Conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V on medicinal products (open-house procedure) Text automatically translated in your browsing language Automatically translated

The present procedure is not subject to public procurement law. This is an open-house procedure. In the interests of transparency and the broadest possible information for interested pharmaceutical companies, this notice shall be published in the Supplement to the Official Journal of the European Union. Insofar as formulations are used in the context of this notice that indicate the award of a public contract, this is solely due to the requirements of this notice form. This and the use of the medium "TED" are not subject to public procurement regulations, the validity of which is not prescribed by law or public procurement regulations and according to the case-law of the European Court of Justice. The open house procedure was already published in the Supplement to the Official Journal of the EU (initial notice) by OJ EU 2023/S 079-237358. The contracting authority has identified the procurement needs for this procedure in OJEU 2023/S 106-334083 (first subsequent notice), OJEU 2023/S 106-334083, OJEU 2023/S 106-334083 (first subsequent notice), OJEU 2023/S 106-334083 (first subsequent notice), OJEU 2023/S 106-334083, p. EU 2024/S 023 67957 (second follow-up notice), OJ 2024/S 067-199292 (third follow-up notice), OJ No. EUR 2024/S 121-372200 (Fourth Follow-up Notice), OJ L 149, 31.12.1924, p. EUR 2024/S 163-503369 (fifth follow-up notice), OJ L 347, 31.12.1924, p. EUR 2024/S 191-589829 (sixth follow-up notice) and OJ No. EUR 2024/S 213-665386 (seventh follow-up notice) extended. The contracting authority has now again expanded the procurement requirements and hereby announces this (eighth follow-up notice) in accordance with its announcement under Section II.2.4) of the initial notice and Section A.I.4.1 of the terms and conditions of participation. AOK Baden-Württemberg (AOK) intends to conclude non-exclusive discount agreements with all suitable pharmaceutical entrepreneurs in accordance with § 130a(8) SGB V on medicinal products with the active substances specified in Annex 3 to the conditions of participation. The duration of rebate contracts for medicinal products containing the active substances published under Section II.2.4) of the initial notice (starting substances, item Nos 1 to 9 of Annex 3 to the Conditions of Participation) shall start at the earliest on 1 July 2023 and shall not exceed 24 months. The duration of rebate contracts for medicinal products with the combination of active substances published in section II.2.4) of the first subsequent notice (item No 10) shall not start before 1.8.2023 and shall not exceed 23 months. The duration of rebate contracts for medicinal products containing the active substance published in point 5.1 of the second subsequent notice (item No 11) shall start at the earliest on 1.4.2024 and shall not exceed 15 months. The duration of rebate contracts for medicinal products containing the active substance published in point 5.1 of the third subsequent notice (items 12 to 16) shall start at the earliest on 1.7.2024 and shall not exceed 12 months. The duration of rebate contracts for medicinal products containing the active substance published in point 5.1 of the fourth subsequent notice (item No 17) shall not start before 1 September 2024 and shall not exceed 10 months. The duration of rebate contracts for medicinal products containing the active substance published under point 5.1 of the fifth subsequent notice (item no. 18) shall start at the earliest on 1.11.2024 and shall not exceed 8 months. The duration of rebate contracts for medicinal products containing the active substance published in point 5.1 of the sixth subsequent notice (item No 19) shall start at the earliest on 1 December 2024 and shall not exceed 7 months. The duration of rebate contracts for medicinal products containing the active substance and combination of active substances (items 20 and 21) published in point 5.1 of the seventh subsequent notice shall start at the earliest on 1.1.2025 and shall not exceed 6 months. The duration of rebate contracts for medicinal products containing the active substance published under point 5.1 of the eighth subsequent notice (item No 22) shall start at the earliest on 1.2.2025 and shall not exceed 5 months. Text automatically translated in your browsing language Automatically translated

33600000 - Pharmaceutical products